While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), many patients ...
Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple cancersNOUS-209 is an ...
Transcriptomic Signatures Associated With Outcomes in Recurrent Prostate Cancer Treated With Salvage Radiation, Androgen-Deprivation Therapy, and Enzalutamide: Correlative Analysis of the STREAM Trial ...
The risk of disease progression or death was reduced by 79% with nivolumab/ipilimumab compared with chemotherapy. The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in ...
Using CRISPR co-culture screens, researchers found that deleting CHD1 and MAP3K7 makes tumor cells more vulnerable to immune ...
Opdivo® (nivolumab) in combination with Yervoy® (ipilimumab) has been made available within NHS Scotland for the first line treatment of adult patients with mismatch repair deficient (dMMR) or ...
Intrapatient Variation in Response to Systemic Therapy in Advanced Hepatocellular Carcinoma The MSI-NGS panel showed 97% accuracy, with 112 patients exhibiting consistent MSI status between samples.
NORTHFIELD, Ill.--(BUSINESS WIRE)--Recognizing a need for evidence-based recommendations to guide molecular testing in the management of patients with cancer, the College of American Pathologists (CAP ...
Panakeia (“the Company”), a pioneer in AI-driven multi-omic biomarker profiling, today announces the launch of PANProfiler Colon, an AI-driven software solution for profiling of Microsatellite ...
Tumors with high levels of microsatellite instability (MSI-H), such as some subsets of colorectal, endometrial and gastric cancers, are associated with a hypermutated phenotype and a specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results